Review article: Clinical significance of mucosal-protective agents: Acid, inflammation, carcinogenesis and rebamipide

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 18, Issue 1, 2003, Pages 153-159

  Haruma, K ^a   Ito, M ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN RADICAL; PROSTAGLANDIN; PROTECTIVE AGENT; REBAMIPIDE; ALANINE; ANTINEOPLASTIC AGENT; ANTIULCER AGENT; DRUG DERIVATIVE; QUINOLONE DERIVATIVE;

ACID SECRETION; BIOSYNTHESIS; BLOOD FLOW; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GASTRITIS; HELICOBACTER PYLORI; HUMAN; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; STOMACH CARCINOGENESIS; STOMACH DISEASE; STOMACH MUCOSA; STOMACH PROTECTION; PHYSIOLOGY; REVIEW; SECRETION; STOMACH ACID; STOMACH TUMOR; VASCULARIZATION;

ALANINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ANTICARCINOGENIC AGENTS; GASTRIC ACID; GASTRIC MUCOSA; GASTRITIS; HUMANS; QUINOLONES; STOMACH NEOPLASMS;

EID: 0043286736     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.18.s1.17.x     Document Type: Conference Paper

References (58)

1. Lam SK. Antacid: the past, the present, and the future. Bail Clin Gastro 1988; 2: 641-54.
2. Lam SK. Differences in peptic ulcer between East and West. Bail Clin Gastro 2000; 14: 41-52.
3. Lam SK, Hassan M, Sircus W, Wong J, Ong GB, Prescott R. Comparison of maximal acid output and gastrin response to meals in Chinese and Scottish normal and duodenal ulcer subjects. Gut 1980; 21: 324-8.
4. Cheng FCY, Lam SK, Ong GB. Maximum acid output to graded doses of pentagastrin and its relation to parietal cell mass in Chinese patients with duodenal ulcer. Gut 1977; 18: 827-32.
5. Burstein M, Monge E, Leon-Barua R, et al. Low peptic ulcer and high gastric cancer prevalence in a developing country with a high prevalence of infection by Helicobacter pylori. J Clin Gastro 1991; 13: 154-6.
6. Kawaguchi H, Haruma K, Komoto K, Yoshihara M, Sumii K, Kajiyama G. Helicobacter pylori infection is the major risk factor for atrophic gastritis. Am J Gastroenterol 1996; 91: 959-62.
7. Haruma K, Mihara M, Okamoto E, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus. Evaluation of 24-h pH monitoring. Aliment Pharmacol Ther 1999; 13: 155-62.
8. Magnusson PKE, Enroth H, Eriksson I, et al. Gastric cancer and human leukocyte antigen: District DQ and DR alleles are associated with development of gastric and infection by Helicobacter pylori. Cancer Res 2001; 61: 2684-9.
9. Kato S, Onda M, Yamada S, Matsuda N, Tokunaga A, Matsukura N. Association of the interleukin-1 β genetic polymorphism and gastric cancer risk in Japanese. J Gastroenterol 2001; 36: 696-9.
10. Furuta T, El-Omar E, Xiao F, Shirai N, Takashima M, Sugiura H. Interleukin 1 β polymorphism increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002; 123: 92-105.
11. Shirasaka D, Aoyama N, Satonaka K, et al. Analysis of Helicobacter pylori vacA gene and serum antibodies to VacA in Japan. Dig Dis Sci 2000; 45: 789-95.
12. Yamaoka Y, Kikuchi S, El-Zimaity HMT, Gutierrez O, Osato MS, Graham DY. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 2002; 123: 414-24.
13. Higashi H, Tsutsumi R, Fujita A, et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci, USA 2002; 99: 14428-33.
14. Blaser MJ, Chyou PH, Nomura A. Age of establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res 1995; 55: 562-5.
15. Haruma K, Kamada T, Kawaguchi H, et al. Effect on age and Helicobacter pylori infection on gastric acid secretion. J Gastro Hepatol 2000; 15: 277-83.
16. Kinoshita Y, Kawanami C, Kishi K, Nakata N, Seino Y, Chiba T. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut 1997; 41: 452-8.
17. Ishihara M, Ito M. Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. Eur J Pharmcol 2002; 444: 209-15.
18. Kuipers EJ, Lundell L, Klinkenberg-knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Medical 1996; 334: 1018-22.
19. Meining A, Bosseckert H, Caspary WF, Nauert C, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of teratment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther 1998; 12: 735-40.
20. Meining A, Kiel C, Stolte M. H2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11: 729-34.
21. Uemura N, Okamoto S, Yamamoto S, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. Aliment Pharmacol Ther 2000; 14: 1345-52.
22. Klinkenberg-knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastro-esophageal reflux disease: Effcacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
23. Asako H, Kubes P, Wallace J, Wolf RE, Granger DN. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology 1992; 103: 146-52.
24. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drag-induced gastric damage. Am J Med 1989; 86: 449-58.
25. Wallace JL, Arfors KE, McKnight GW. A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. Gastroenterology 1991; 100: 878-83.
26. Yoshida N, Takemura T, Granger DN, et al. Molecular determinants of aspirin-induced neutrophil adherence to endothelial cells. Gastroenterology 1993; 105: 715-24.
27. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
28. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13.
29. Maiden LP, Harris AW, Lai KC, Hui WM, Lam SK. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin. N Engl J Med 2002; 347: 1623-4.
30. Murakami K, Okajima K, Uchiba M, et al. Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Dig Dis Sci 1997; 42: 319-25.
31. Kim CD, Kim YK, Lee SH, Hong KW. Rebamipide inhibits neutrophil adhesion to hypoxia/reoxygenation-stimulated endothelial cells via nuclear factor-κB-dependent pathway. J Pharmacol Exp Ther 2000; 294: 864-9.
32. Murakami K, Okajima K, Harada N, Isobe H, Okabe H. Rebamipide prevents indomethacin-induced gastric mucosal lesion formation by inhibiting activation of neutrophil in rats. Dig Dis Sci 1998; 43: 139S-42S.
33. Kim CD, Kim HH, Hong KW. Inhibitory effect of rebamipide on the neutrophil adherence stimulated by conditioned media from Helicobacter pylori infected gastric epithelial cells. J Pharmacol Exp Ther 1999; 288: 133-8.
34. Yoshida N, Yoshikawa T, Iinuma S, et al. Rebamipide protects against activation of neutrophil by Helicobacter pylori. Dig Dis Sci 1996; 41: 1139-44.
35. Yamasaki K, Kanbe T, Chijiwa T, Ishiyam H, Morita S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol 1987; 142: 23-9.
36. Kline A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 1993; 38: 1441-9.
37. Naito Y, Yoshikawa T, Iinuma S, et al. Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci 1998; 43(9 Suppl.): 83S-9S.
38. Ito M, Haruma K, Kaya S, et al. Role of anti-parietal cell antibody on atrophic gastritis in Helicobacter pylori-positive patients: evaluation in a country of high prevalence of atrophic gastritis. Scand J Gastroenterol 2002; 37: 287-93.
39. Ito M, Haruma K, Kaya S, et al. Implication of anti-parietal cell antibody levels in gastrointestinal diseases: including gastric carcinogenesis. Dig Dis Sci 2002; 47: 1080-5.
40. Ito M, Haruma K, Kamada T, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002; 16: 1449-56.
41. Haruma K, Ito M, Kido S, et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci 2002; 47: 862-7.
42. Masamune A, Yoshida M, Sakai Y, Shimosegawa T. Rebamipide inhibits ceramide-induced interleukin-8 production in Kato III human gastric cancer cells. J Pharmacol Exp Ther 2001; 298: 485-92.
43. Aihara M, Azuma A, Takizawa H, et al. Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci 1998; 43(9 Suppl.): 174S-80S.
44. Choi KW, Lee YC, Chang IS, et al. Effect of rebamipide in treatment of Helicobacter pylori-associated duodenal ulcer: attenuation of chemokine expression and nitrosative damage. Dig Dis Sci 2002; 47: 283-91.
45. Asahi M, Azuma T, Ito S, et al. Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. J Exp Med 2000; 191: 593-602.
46. Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 25(295): 683-6.
47. Iwai A, Iwashita E. Changes in colonic inflammation induced by dextran sulfate sodium (DDS) during short-and long-term administration of rebamipide. Dig Dis Sci 1998; 43: 143S-7S.
48. Makiyama K, Takeshita F. Anti-inflammatory effect of rebamipide enema on proctttis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol 2000; 95: 1838-9.
49. Natio Y, Yoshikawa T. Molecular and cellular mechanisms involved in Helicobacter pylori-induced inflammation and oxidative stress (1,2). Free Radio Biol Med 2002; 33: 323-36.
50. Yoshikawa T, Natio Y, Tanigawa T, Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneim-Forsh/Drug Res 1993; 43: 363-6.
51. Suzuki M, Miura S, Mori M, et al. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut 1994; 35: 1375-8.
52. Naito Y, Yoshikawa T, Tanigawa T, et al. Hydroxy radical scavenging by rebamupide and related compounds: electron paramagnetic resonance study. Free Rad Bio Med 1995; 18: 117-23.
53. Hong WS, Jung HY, Yang SK, et al. The antioxidant effect of rebamipide on oxygen free radical production by H.pylori-activated human neutrophils: in comparison with N-acetylcysteine, ascorbic acid and glutathione. Pharm Res 2001; 44: 273-7.
54. Yoshikawa T, Naito Y, Nakamura S, et al. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indomethacin in rats. Arzneim-Forsh/Drug Res 1993; 43(II.12): 1327-30.
55. Goto T, Haruma K, Kitadai Y, et al. Enhanced expression of inducible Nitric Oxide Synthase and Nitrotyrosine in gastric mucosa of gastric cancer patients. Clin Cacner Res 1999; 5: 1411-5.
56. Hahm KB, Lee KJ, Kim JH, Cho SW, Chung MH. Helicobacter pylori infection, oxidative DNA damage, gastric carcinogenesis, and reversibility by rebamipide. Dig Dis Sci 1998; 43(Suppl. 9): 72S-7S.
57. Mowat C, Williams C, Gillen D, et al. Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-Nitrosation. Gastroenterology 2000; 119: 339-47.
58. Correa PA. Human model of gastric carcinogenesis. Cancer Res 1988; 48: 3554-60.